Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Glycosylated hemoglobin (HbA1c) 7.5%-11% at screening, and 7.0%-10.0% pre-randomization~2. FPG 7.0 mmol/L-11.0mmol/L at screening and pre-randomization~3. Body mass index (BMI) 18.5 and-35.0 kg/m2 at screening~4. Antidiabetics-naive within 2 months before screening~Exclusion Criteria:~1. Diagnosis of type 1 diabetes mellitus or secondary forms of diabetes~2. History of febrile illness within 5 days prior to dosing~3. Medical history of myocardial infarction, angina/unstable angina, coronary revascularization, stroke or transient ischemic attack~4. Any medical history or current clinical evidence of congestive heart failure, New York Heart Association (NYHA) Functional Classification, Classes II-IV~5. Episode(s) of hypoglycemia adverse events (HAE) of 'severe' intensity prior to screening; either:~   1. \>1 in the previous 3 months; or~  2. \>2 in the previous 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PB-201 50/50mg by mouth,every morning and noon for 7 days (Type: EXPERIMENTAL): None
- PB-201 100/50mg by mouth,every morning and noon for 7 days (Type: EXPERIMENTAL): None
- PB-201 100/100mg by mouth,every morning and noon for 7 days (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).